Partner in care

Partner in relief

DUPIXENT is a biologic with a
novel approach to treating
moderate-to-severe atopic
dermatitis in patients aged
12 years and older1

Consider referring to a
today to see what’s
possible with DUPIXENT

When topical Rx therapies aren’t enough, DUPIXENT may be appropriate

Patients may be appropriate for DUPIXENT if they:

  • Have tried a variety of topical prescription therapies and are still uncontrolled
  • Suffer from inadequate control of pruritus
  • Have ≥10% of their body covered with lesions and/or may involve problem areas such as the face, hands, and feet
  • Have moderate‑to‑severe erythema and moderate-to-severe papulation/infiltration (IGA 3=moderate or 4=severe)

Consider referring your patients to a specialist today

Partner with an eczema specialist to help your patients. Use the HealthgradesTM tool to easily find nearby eczema specialists with experience in treating adolescents and adults with uncontrolled moderate-to-severe atopic dermatitis.

Other treatments don’t specifically target key sources of underlying inflammation2

Atopic dermatitis is a chronic, recurring, and systemic disease, leaving patients trapped in an endless cycle of flares driven in part by persistent underlying inflammation.2,3

DUPIXENT targets a key source of the underlying inflammation of atopic dermatitis1

Even when patients are not in a flare, they continue to experience underlying inflammation2

DUPIXENT systematically addresses inflammation in a more targeted manner than topical Rx therapies and systemic steroids1-4

Topical Rx therapies may not be enough to treat moderate-to-severe atopic dermatitis2,4,5

DUPIXENT is Revolutionizing
Atopic Dermatitis

DUPIXENT has proven efficacy and demonstrated long-term safety in moderate‑to‑severe atopic dermatitis uncontrolled with topical Rx therapy1

Itch relief1

Clear or almost-clear skin and improvement in lesion extent and severity1

Demonstrated safety profile1

DUPIXENT is not an
immunosuppressant or a

There is no requirement for
initial lab testing or ongoing
lab monitoring according to
the Prescribing Information1

The most common adverse reactions (incidence ≥1% at Week 16) were injection site reactions, conjuctivitis, blepharitis, oral herpes, keratitis, eye pruritis, other herpes simplex virus infection, and dry eye1

a IQVIA National Prescription Audit (NPA) data as of September 2019. b New patients across all indications.

Trial Designs and Results